Nobivac L4

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Interrogans серовара лептоспир серогруппы Кашницкого Portland-vjeri (soj Sa-12-000) i L. interrogans серовара Copenhageni серогруппы Icterohaemorrhagiae (soj SC-02-001), l. interrogans серогруппы Аустралис серовара Bratislava (soj Ac-05-073), l. kirschneri серогруппы Grippotyphosa серовара Dadas (soj gr-01-005)

Available from:

Intervet International BV

ATC code:

QI07AB01

INN (International Name):

Vaccine to prevent Leptospira infections in dogs

Therapeutic group:

psi

Therapeutic area:

Immunologicals

Therapeutic indications:

Za aktivnu cijepljenja pasa protiv:interrogans серовара лептоспир серогруппы Кашницкого Тянитолкая za smanjenje infekcije i izlučivanje;l. interrogans серогруппы Icterohaemorrhagiae Copenhageni серовара za smanjenje infekcije i izlučivanje;l. interrogans серогруппы Аустралис серовара Bratislava za smanjenje infekcije;l. kirschneri serogroup Grippotyphosa serovar Bananal / Lianguang za smanjenje infekcije i izlučivanje urina.

Product summary:

Revision: 6

Authorization status:

odobren

Authorization date:

2012-07-16

Patient Information leaflet

                                14
B.
UPUTA O VMP
15
UPUTA O VMP
NOBIVAC L4 SUSPENZIJA ZA INJEKCIJU ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
PROIZVODNE SERIJE, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za
puštanje serije u promet:
Intervet International B.V.
Wim de Körverstraat 35
NL-5831 AN Boxmeer
Nizozemska
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobivac L4 suspenzija za injekciju za pse
3.
NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
Svaka doza od 1 ml sadrži :
DJELATNA TVAR:
Inaktivirani sojevi
_Leptospira _
:
-
_L. interrogans, _
serogrupa Canicola, serovar Portland-vere (soj Ca-12-000)
3550 - 7100 U
1
-
_ L. interrogans,_
serogrupa Icterohaemorrhagiae, serovar Copenhageni
290 - 1000 U
1
(soj Ic-02-001)
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava
(soj As-05-073)
500 - 1700 U
1
-
_ L. kirschneri,_
serogrupa Grippotyphosa, serovar Dadas
(soj Gr-01-005)
650 - 1300 U
1
1
Antigena masa ELISA jedinice.
Bezbojna suspenzija.
4.
INDIKACIJE
Za aktivnu imunizaciju pasa protiv:
-
_L. interrogans, _
serogrupa Canicola, serovar Canicola, za smanjenje infekcije i
izlučivanja putem
urina,
-
_L. interrogans, _
serogoupa Icterohaemorrhagiae, serovar Copenhagen, za smanjenje
infekcije i
izlučivanja putem urina,
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava, za smanjenje infekcije,
-
_L. kirschneri, _
serogrupa Grippotyphosa, serovar Bananal/Lianguang, za smanjenje
infekcije i
izlučivanja putem urina.
Početak imunosti: 3 tjedna.
Trajanje imunosti: 1 godina.
5.
KONTRAINDIKACIJE
Nema.
16
6.
NUSPOJAVE
Prolazno, blago povećanje tjelesne temperature (
≤
1
°
C) često se pojavljuje nekoliko dana nakon
cijepljenja uz smanjenu aktivnost i/ili smanjen apetit kod nekih
štenaca. Mala prolazna oteklina na
mjestu injekcije (
≤
4 cm), koja se često pojavljivala u kliničkim ispitivanjima, ponekad
može biti tvrda
i bolna na dodir. Oteklina će se znatno smanjiti ili će sasvim
nestati do 1
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Nobivac L4, suspenzija za injekciju za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza od 1 ml sadrži :
DJELATNA TVAR:
Inaktivirani sojevi
_Leptospira _
:
-
_L. interrogans, _
serogrupa Canicola, serovar Portland-vere (soj Ca-12-000)
3550 - 7100 U
1
-
_ L. interrogans,_
serogrupa Icterohaemorrhagiae, serovar Copenhageni
290 - 1000 U
1
(soj Ic-02-001)
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava
(soj As-05-073)
500 - 1700 U
1
-
_ L. kirschneri,_
serogrupa Grippotyphosa, serovar Dadas
(soj Gr-01-005)
650 - 1300 U
1
1
Antigena masa ELISA jedinica.
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
3.
FARMACEUTSKI OBLIK
Suspenzija za injekciju.
Bezbojna suspenzija.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi.
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Za aktivnu imunizaciju pasa protiv:
-
_L. interrogans, _
serogrupa Canicola, serovar Canicola, za smanjenje infekcije i
izlučivanja putem
urina,
-
_L. interrogans, _
serogoupa Icterohaemorrhagiae, serovar Copenhagen, za smanjenje
infekcije i
izlučivanja putem urina,
-
_L. interrogans, _
serogrupa Australis, serovar Bratislava, za smanjenje infekcije,
-
_L. kirschneri, _
serogrupa Grippotyphosa, serovar Bananal/Lianguang, za smanjenje
infekcije i
izlučivanja putem urina.
Početak imunosti: 3 tjedna.
Trajanje imunosti: 1 godina.
4.3
KONTRAINDIKACIJE
Nema.
4.4
POSEBNA UPOZORENJA ZA SVAKU CILJNU VRSTU ŽIVOTINJA
Cijepiti samo zdrave životinje.
3
4.5
POSEBNE MJERE PREDOSTROŽNOST ZA PRIMJENU
Posebne mjere predostrožnost za primjenu na životinjama
Nije primjenjivo.
Posebne mjere predostrožnost koje mora poduzeti osoba koja
primjenjuje veterinarsko-medicinski
proizvod na životinjama
Izbjegavati slučajno samoinjiciranje ili kontakt s očima. U slučaju
iritacije očiju odmah potražite
liječničku pomoć i pokažite liječniku uputu ili naljepnicu koja
se nalazi u pakiranju.
4.6
NUSPOJAVE (UČESTALOST I OZBILJNOST)
Prolazno, blago pov
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 11-11-2021
Public Assessment Report Public Assessment Report Bulgarian 29-01-2013
Patient Information leaflet Patient Information leaflet Spanish 11-11-2021
Public Assessment Report Public Assessment Report Spanish 29-01-2013
Patient Information leaflet Patient Information leaflet Czech 11-11-2021
Public Assessment Report Public Assessment Report Czech 29-01-2013
Patient Information leaflet Patient Information leaflet Danish 11-11-2021
Public Assessment Report Public Assessment Report Danish 29-01-2013
Patient Information leaflet Patient Information leaflet German 11-11-2021
Public Assessment Report Public Assessment Report German 29-01-2013
Patient Information leaflet Patient Information leaflet Estonian 11-11-2021
Public Assessment Report Public Assessment Report Estonian 29-01-2013
Patient Information leaflet Patient Information leaflet Greek 11-11-2021
Public Assessment Report Public Assessment Report Greek 29-01-2013
Patient Information leaflet Patient Information leaflet English 11-11-2021
Public Assessment Report Public Assessment Report English 29-01-2013
Patient Information leaflet Patient Information leaflet French 11-11-2021
Public Assessment Report Public Assessment Report French 29-01-2013
Patient Information leaflet Patient Information leaflet Italian 11-11-2021
Public Assessment Report Public Assessment Report Italian 29-01-2013
Patient Information leaflet Patient Information leaflet Latvian 11-11-2021
Public Assessment Report Public Assessment Report Latvian 29-01-2013
Patient Information leaflet Patient Information leaflet Lithuanian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 11-11-2021
Public Assessment Report Public Assessment Report Lithuanian 29-01-2013
Patient Information leaflet Patient Information leaflet Hungarian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 11-11-2021
Public Assessment Report Public Assessment Report Hungarian 29-01-2013
Patient Information leaflet Patient Information leaflet Maltese 11-11-2021
Public Assessment Report Public Assessment Report Maltese 29-01-2013
Patient Information leaflet Patient Information leaflet Dutch 11-11-2021
Public Assessment Report Public Assessment Report Dutch 29-01-2013
Patient Information leaflet Patient Information leaflet Polish 11-11-2021
Public Assessment Report Public Assessment Report Polish 29-01-2013
Patient Information leaflet Patient Information leaflet Portuguese 11-11-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 11-11-2021
Public Assessment Report Public Assessment Report Portuguese 29-01-2013
Patient Information leaflet Patient Information leaflet Romanian 11-11-2021
Public Assessment Report Public Assessment Report Romanian 29-01-2013
Patient Information leaflet Patient Information leaflet Slovak 11-11-2021
Public Assessment Report Public Assessment Report Slovak 29-01-2013
Patient Information leaflet Patient Information leaflet Slovenian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 11-11-2021
Public Assessment Report Public Assessment Report Slovenian 29-01-2013
Patient Information leaflet Patient Information leaflet Finnish 11-11-2021
Public Assessment Report Public Assessment Report Finnish 29-01-2013
Patient Information leaflet Patient Information leaflet Swedish 11-11-2021
Public Assessment Report Public Assessment Report Swedish 29-01-2013
Patient Information leaflet Patient Information leaflet Norwegian 11-11-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 11-11-2021
Patient Information leaflet Patient Information leaflet Icelandic 11-11-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 11-11-2021

View documents history